FDA/CDC
FDA/CDC
Pain frequency varies by employment status
Previously employed adults are the most likely to experience daily pain.
News from the FDA/CDC
Opioid prescribing drops nationally, remains high in some counties
The CDC calls for “more consistency among health care providers” when it comes to prescribing opioids.
FDA/CDC
Endo removes Opana ER from market
The move is in compliance with an FDA request citing a spike in abuse of the opioid agonist.
FDA/CDC
Cotempla XR-ODT approved for children, adolescents with ADHD
Methylphenidate for ADHD now comes in a more convenient disintigrating tablet.
FDA/CDC
Mydayis approved for teens, adults with ADHD
Treatment can lead to improved symptoms of ADHD that can last up to 16 hours, phase III studies show.
FDA/CDC
Extended-release Aristada OK’d for 2-month dosing for schizophrenia
The new bimonthly long-acting injectable is another option aimed at improving adherence among patients.
FDA/CDC
FDA approves generic Strattera for pediatric, adult ADHD patients
Generic atomoxetine will help more people in need find treatment.
FDA/CDC
Alzheimer’s mortality in U.S. grew from 1999 to 2014
Mortality rose dramatically in some states and ethnicities.
FDA/CDC
FDA approves new treatment for episodic cluster headaches in adults
The Food and Drug Administration announced April 18 the approval of the gammaCore device to treat pain associated with episodic cluster headache...
FDA/CDC
FDA approves deutetrabenazine for Huntington’s-associated chorea
Deutetrabenazine is only the second product approved to treat Huntington’s in any capacity, and it is the first in nearly a decade.
FDA/CDC
FDA approves safinamide to treat Parkinson’s disease
The drug is indicated for use as an add-on to levodopa or carbidopa to help in reducing “off” time.